Key Highlights

100% ORR in early data (evaluable patients)
No Grade ≥3 CRS or ICANS observed
Dual-targeting (BCMA + CD19)
Faster manufacturing timeline (about 14 days)

Designed for patients who have received at least 3 prior lines, including PI, IMiD, and anti-CD38 therapy.

Next Generation CAR-T Therapy Clinical Trial #23586

Refer eligible patients for a Phase 1b/2 study evaluating AZD0120 (BCMA/CD19 CAR-T) with early signals of deep response and favorable safety.

A Potential Next Step for Unresponsive Myeloma Patients

Patients with RRMM who have progressed after standard therapies often face limited options. AZD0120 is designed to:

Target two antigens (BCMA + CD19) to reduce tumor escape
Deliver rapid and deep responses
Maintain a manageable safety profile

Early Clinical Results Show Promise

Results from Phase 1b. Highlights below or read the published study.

Efficacy

ORR: 100% (n=15 evaluable)
33% sCR / 47% VGPR
100% MRD negativity (evaluable pts)
Median time to response: about 1 month

Safety

No Grade ≥3 CRS
No ICANS observed
CRS mostly Grade 1–2, short duration (about 2 days)

Operational Advantage

Manufacturing: about 14 days
Vein-to-vein: about 28 days
Utilizes FasTCAR Technology

Note: Data is early phase with limited follow-up. ORR (Overall Response Rate), sCR (Stringent Complete Response), VGPR (Very Good Partial Response), MRD negativity (Minimal or Measurable Residual Disease negativity), CRS (Cytokine Release Syndrome), ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome),

Which Patients May Be Eligible?

Inclusion Criteria Summary:

Relapsed/refractory multiple myeloma
≥3 prior lines of therapy
Prior PI + IMiD + anti-CD38
ECOG 0–1
Adequate organ function

Exclusion Criteria Summary:

Active CNS involvement
Significant cardiac disease
Recent stem cell transplant

Review full clinical trial details

Not sure if your patient qualifies? Contact a Clinical Research Coordinator for rapid eligibility review: Garrett.Welch@moffitt.org

What does trial participation look like for patients?

Submit referral request and send patient records to Moffitt
Patients will be pre-screened for basic eligibility by the clinical research coordinator
Initial appointment with Dr. Hansen
Workup and clinical screening appointments
Following enrollment in the trial, patient is scheduled for apheresis and chemotherapy
Apheresis (cell collection) is a half-day appointment at Magnolia Campus
Collected cells are sent for manufacturing (about two weeks). Patients usually remain at home during cell manufacturing process
Patient receives infusion of cells at Magnolia Campus

The patient and their caregiver will need to remain within 1 hour of Moffitt's Magnolia Campus for about 28 days after infusion of cells, for careful monitoring and multiple visits. The trial sponsor will reimburse travel expenses and our team can support with finding accomodations for patients who live further away.

Expenses Reimbursed

Travel, lodging and meals expenses are covered by the trial sponsor from the first visit/screening through the 2 year follow up period via reimbursement
Follow-up Care

There are 2 years of active follow-up care. This is followed up by care visits every 6 months until 15 years post therapy.

Partner with Moffitt

A referral for a clinical trial means we will work together to give your patient the best chance at beating their cancer.

For patients with RRMM who have exhausted standard options, this dual-target CAR-T approach represents a promising next step. We are encouraged by the early depth of response and the manageable profile observed to date.

Doris Hansen, MD

Principal Investigator

Have a patient you think would be a candidate for this clinical trial?

We are here to help, you can start a referral by submitting this online form.

If you have questions for the Research Coordinator about the trial, please contact Garrett.Welch@moffitt.org.

For questions about referring your patient or to learn more about Moffitt you can speak with a Physician Liaison:

Contact Your Physician Liaison

Clinical Trial Referral Form

Patient Information

Patient First Name

Patient Last Name

Patient Date of Birth

Patient Phone Number

Patient Alternate Phone Number

Patient Email Address

Patient Street Address

Patient City

Patient State

Patient Zip Code

Patient Insurance Information

Patient Primary insurance

Referring Provider Information

Are you a patient or a referring provider?

Referring Physician First Name

Referring Physician Last Name

Referring Physician Phone Number

World Leader in CAR T Therapy

As the first cancer center worldwide to treat over 2,000 patients with CAR T therapy, Moffitt is a world leader in CAR T, pioneering next-generation cell therapies and TILs to harness the power of the immune system.

Request an Appointment